sr141716 has been researched along with Cholera Infantum in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fabisiak, A; Fabisiak, N; Fichna, J; Storr, M; Włodarczyk, M | 1 |
| Bhatt, DL; Bousser, MG; Cohen, E; Creager, MA; Despres, JP; Easton, JD; Fox, KA; Gaudin, C; Hamm, CW; Job, B; Montalescot, G; Murphy, JH; Pearson, TA; Steg, PG; Topol, EJ | 1 |
1 review(s) available for sr141716 and Cholera Infantum
| Article | Year |
|---|---|
Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis.
Topics: Amides; Cannabinoid Receptor Antagonists; Constipation; Gastrointestinal Agents; Gastrointestinal Diseases; Humans; Irritable Bowel Syndrome; Mental Disorders; Pyridines; Rimonabant | 2019 |
1 trial(s) available for sr141716 and Cholera Infantum
| Article | Year |
|---|---|
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Double-Blind Method; Drug Approval; Female; Gastrointestinal Diseases; Humans; Male; Mental Disorders; Obesity; Piperidines; Pyrazoles; Rimonabant; Suicide | 2010 |